RxDoctor Payments Data

Carlos Quiros, MD

Family Medicine · Bonita, CANPI 1679502884

Payments from drug & device makers

$1,751in general payments, 2019–2025

Across 77 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$285
  • Gilead$262
  • GSK$250
  • Lilly USA, LLC$229
  • Novo Nordisk$161
  • AstraZeneca$125
  • plus $439 from 11 others

What the payments were for

  • Food & beverage$1,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,751 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$164,474
Medicare patients
820
Services billed
2,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$44,218
FarxigaDapagliflozin Propanediol38$38,472
JardianceEmpagliflozin23$36,496
OzempicSemaglutide37$36,083
XareltoRivaroxaban16$23,278
Synjardy XrEmpagliflozin/Metformin Hcl11$16,547
JanuviaSitagliptin Phosphate15$12,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,659
MyrbetriqMirabegron14$6,198
SymbicortBudesonide/Formoterol Fumarate14$4,131
Atorvastatin Calcium256$2,890
Valsartan84$2,810
Gabapentin51$2,324
Tamsulosin Hcl88$1,908
Levothyroxine Sodium117$1,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$285$53,04334 claims
PfizerEliquis$44$44,21835 claims
AstraZenecaFarxiga, Symbicort$125$42,60352 claims
Novo NordiskOzempic$161$36,08337 claims
GSKTrelegy Ellipta$250$11,65916 claims
Astellas Pharma US IncMyrbetriq$14$6,19814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Bonita

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →